NIA Schedules Closed Meeting on Alzheimer's Grants
Published Date: 3/28/2025
Notice
Summary
The National Institute on Aging is holding a private virtual meeting on May 2, 2025, to review grant applications for Alzheimer's drug trials. This meeting affects researchers seeking funding and keeps sensitive info safe. No money changes are announced, but the review helps decide who gets research support.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Alzheimer's Grant Applications Reviewed
On May 2, 2025, from 3:30 p.m. to 5:30 p.m., the National Institute on Aging will hold a closed virtual meeting to review and evaluate grant applications for AD (Alzheimer's disease) clinical drug trials. If you are a researcher who applied for these grants, this review is the official step that helps decide who receives research support.
Confidentiality Protected in Closed Review
The meeting will be closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6) because grant discussions could reveal confidential trade secrets, patentable material, or personal information. This closure protects applicants' sensitive commercial and personal information during the May 2, 2025 virtual review.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-05288, Polyester Textured Yarn From India: Preliminary Results of Antidumping Duty Administrative Review; 2023
The U.S. Department of Commerce checked if polyester textured yarn from India was sold too cheaply in 2023 and found it wasn’t. This means no extra taxes (antidumping duties) will be added for now. Companies involved should keep an eye out and can share their thoughts before the final decision.
Next: 2025-05290, National Institute on Drug Abuse; Cancellation of Meeting
The National Institute on Drug Abuse canceled its special meeting set for April 3, 2025, and won’t reschedule it. This affects researchers and participants who planned to join, but no money or deadlines are changing. If you were gearing up for this event, you can relax and adjust your plans now!